Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
I'm PortAI, I can summarize articles.
Rani Therapeutics has signed a licensing deal with Chugai Pharmaceutical worth up to $1.09 billion to develop an oral version of an experimental antibody. The agreement includes a $10 million upfront payment, potential milestones totaling $175 million, and royalties on sales. Rani's shares surged nearly threefold in premarket trading following the announcement. This partnership leverages Rani's oral drug delivery technology and Chugai's expertise in complex antibodies, according to CEO Talat Imran.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments